- NYSE:AMC fell by 15.8% during Wednesday’s trading session.
- The CDC officially finds its first case of the Omicron variant in the United States.
- AMC experienced its busiest ticket selling day since the pandemic started.
UPDATE: AMC shares fell 0.4% to $28.41 about 90 minutes into Thursday's session. The movie theatre meme stock was up a similar amount at the open but could not hold the price level. If AMC price stays red by the close, then this will be the seventh straight session where it lost ground.
NYSE:AMC extended its recent losing streak to six straight sessions on Wednesday, as global markets continued to see volatility on the first trading day of December. Shares of AMC hit free fall and plunged by 15.82%, closing the tumultuous session at $28.57. The stock is trading well below both its 50-day and 200-day moving averages now, and on Wednesday AMC saw its lowest closing price since May. There does not seem to be much that can stop the bleeding right now for AMC, as the company lacks any sort of market moving catalysts aside from the releases of upcoming Hollywood blockbusters during the holiday season.
Stay up to speed with hot stocks' news!
The major news that shocked the markets on Wednesday was that the CDC has officially reported its first case of the Omicron variant in California. The discovery has major repercussions if the variant manages to spread as rapidly as it did in South Africa. AMC would likely suffer from another period of low attendance if public health authorities provide a new public health order for COVID-19 safety protocols. Unfortunately for retailers like AMC, we find ourselves without an end in sight to the ongoing pandemic.
AMC stock forecast
In a bit of contrary news, AMC reported its busiest day for ticket sales since the pandemic started. On Monday, presales for the new Sony and Marvel film Spiderman: No Way Home began, and some domestic ticket sites crashed due to the high volume. It is one of the most anticipated films of the holiday season, although it will be interesting to see if rising cases of the Omicron variant puts a damper on the box office numbers.
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD edges lower toward 1.0700 post-US PCE
EUR/USD stays under modest bearish pressure but manages to hold above 1.0700 in the American session on Friday. The US Dollar (USD) gathers strength against its rivals after the stronger-than-forecast PCE inflation data, not allowing the pair to gain traction.
GBP/USD retreats to 1.2500 on renewed USD strength
GBP/USD lost its traction and turned negative on the day near 1.2500. Following the stronger-than-expected PCE inflation readings from the US, the USD stays resilient and makes it difficult for the pair to gather recovery momentum.
Gold struggles to hold above $2,350 following US inflation
Gold turned south and declined toward $2,340, erasing a large portion of its daily gains, as the USD benefited from PCE inflation data. The benchmark 10-year US yield, however, stays in negative territory and helps XAU/USD limit its losses.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
Week ahead – Hawkish risk as Fed and NFP on tap, Eurozone data eyed too
Fed meets on Wednesday as US inflation stays elevated. Will Friday’s jobs report bring relief or more angst for the markets? Eurozone flash GDP and CPI numbers in focus for the Euro.